Compare SIDU & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIDU | TNXP |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.0M | 172.7M |
| IPO Year | 2021 | 2008 |
| Metric | SIDU | TNXP |
|---|---|---|
| Price | $2.18 | $11.98 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 6.6M | 375.9K |
| Earning Date | 05-14-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 84.42 | ★ 91.75 |
| EPS | ★ N/A | N/A |
| Revenue | $4,672,646.00 | ★ $13,107,000.00 |
| Revenue This Year | N/A | $566.15 |
| Revenue Next Year | $100.00 | $36.04 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 29.85 |
| 52 Week Low | $0.63 | $12.70 |
| 52 Week High | $5.39 | $69.65 |
| Indicator | SIDU | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 46.37 | 35.47 |
| Support Level | $0.89 | N/A |
| Resistance Level | $2.19 | $20.36 |
| Average True Range (ATR) | 0.31 | 1.06 |
| MACD | 0.03 | -0.13 |
| Stochastic Oscillator | 16.81 | 7.92 |
Sidus Space Inc is a Space and Defense as-a-Service company focused on providing complex space hardware, satellite/spacecraft design, manufacture, launch, and data solutions for both government and commercial in-space missions for all destinations through the solar system. This includes a Space-based infrastructure of multi-mission satellites with hyperspectral, multi-spectral, and other sensors to provide monitoring services and solutions to multiple sectors and industries. The company supports Commercial Space, Aerospace, Defense, Underwater Marine, and other commercial and government customers.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.